DNLI
Denali Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.34B
P/E Ratio
—
EPS
$-2.88
Beta
1.01
52W High
$23.77
52W Low
$12.58
50-Day MA
$19.68
200-Day MA
$18.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-406.40M |
| EBITDA | $-531.76M |
| Operating Margin | 0.00% |
| Return on Equity | -49.60% |
| Return on Assets | -27.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.84 |
| Price-to-Book | 3.71 |
| Price-to-Sales (TTM) | 3643.65 |
| EV/Revenue | 2843.16 |
| EV/EBITDA | 86.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $158.71M |
| Float | $144.23M |
| % Insiders | 9.15% |
| % Institutions | 99.58% |
Historical Volatility
HV 10-Day
54.75%
HV 20-Day
51.68%
HV 30-Day
50.18%
HV 60-Day
61.68%
HV Rank
22.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($33.93 target)
1
Strong Buy17
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026